68 results about "Arterial occlusions" patented technology

A neural stimulation therapy system for atherosclerotic plaques is provided. One aspect of this disclosure relates to a medical device for applying neural stimulation therapy for atherosclerotic plaques. The device includes a neural stimulator adapted to deliver an electrical signal through at least one electrode to an autonomic neural target. The device also includes a controller to control the neural stimulator to provide a therapy for atherosclerotic plaques. The device is external to a human body in an embodiment, and includes an implantable medical device (IMD) in various embodiments. According to an embodiment, the device includes a neural stimulation lead connected to the neural stimulator. The neural stimulator delivers electrical signals with waveform parameters based on sensed arterial blockage levels, according to various embodiments. Other aspects and embodiments are provided herein.

Disclosed is a conduit that provides a bypass around a stenosis or occlusion in a coronary artery. The conduit is adapted to be positioned in the myocardium to provide a passage for blood to flow from a heart chamber to a coronary artery, at a site distal to the blockage or stenosis in the coronary artery. The conduit has a one-way valve positioned therein to prevent the backflow of blood from the coronary artery into the heart chamber.

Methods are provided for partial aortic obstruction for cerebral perfusion augmentation in patients suffering from global or focal cerebral ischemia. Alternatively, the methods can be used to partially obstruct aortic blood flow to condition the spinal cord to secrete neuroprotective agents prior to abdominal aortic aneurysm repair. Partial obstruction of a vessel can be accomplished by a device comprising an elongate catheter and a distally mounted expandable member. The expandable member may comprise one or two balloons. Other medical devices, such as an angioplasty, stent, or atherectomy catheter, can be inserted distal the expandable member to provide therapeutic intervention.

The invention discloses an instrument for arterial occlusion lesion treating and the application thereof. The instrument comprises a vascular ultrasound catheter, a treating micro catheter and a treating guiding line. The vascular ultrasound catheter and the treating micro catheter are integrally connected in parallel. One part of the treating guiding line is placed in the treating micro catheter, and the other part of the treating guiding line penetrates out of the treating micro catheter from a side wall outlet. According to the instrument, the vascular ultrasound catheter and the treating micro catheter are integrally connected in parallel, a double-cavity micro catheter is used for adjusting the treating guiding line to enter a vessel true lumen, thrombus is sucked out through the treating guiding line, and post-operation hidden danger is removed through one-time curing. The problem that in an intervention recanalization treating operation of blocking of coronary arteries, peripheral arteries and other organ pipelines, a treating guiding line cannot enter a true lumen easily is solved.

The invention relates to prostaglandin microemulsion-gel preparation and a preparation method thereof. The preparation comprises prostaglandin E1 or the derivative thereof, oil, emulsifier, assistant for emulsifying agent, gel substrate and water, and also possibly comprises a permeation accelerator, a preparation stabilizer, an antioxidant and antiseptics. The preparation has the advantages of good percutaneous permeability, no stimulation to skin and mucous membrane, simple preparation technique and stable quality, the preparation can be used for treating diseases such as ulcer of limbs caused by erectile dysfunction and chronic arterial occlusion and rest pain of limbs caused by microcirculatory disturbance.

The use of a collagenase containing formulation for degrading collagen within an occlusive atherosclerotic plaque in a chronic fibrotic occlusion, chronically occluded animal tube or cavity. A medical-related apparatus is provided comprising a medical-related device having provided thereto a therapeutic amount of a collagen degrading composition comprising a proteiolytic enzyme containing formulation. A method is provided for treating chronically occluded animal tubes and cavities by administering a therapeutic effective amount of a proteolytic enzyme-containing formulation adjacent to an occluding atherosclerotic plaque, waiting for a pre-angioplasty waiting period, followed by crossing the plaque with an angioplasty guide wire.

The invention provides phascolosoma esculenta plasmin, which is extracted from phascolosoma esculenta, and has double activities of directly dissolving fibrin and kinase. The phychemical performance of the plasmin is that: the molecular weight is between 28,000 and 32,000, the isoelectric point is between 4.6 and 6.6, the dissolution activity of fibrin does not change greatly under a temperature range between 30 and 70 DEG C, and the stability range to the pH value is between 5.0 and 9.0. The phascolosoma esculenta plasmin has the direct fibrin and kinase dissolving activities, has simple extracting process, low preparation cost and easily obtained raw materials, can be developed into intravenous injection, contains the plasmin capable of directly dissolving thrombus, and is expected to obtain better effect in treating catheter assisted thrombolysis treating peripheral arterial occlusion and deep venous thrombosis.

This invention relates to a new type of apparatus designed to modulate the neurovegetative system and integrate the neurovegetative action with that of the central nervous system. The method is not invasive, because it uses pulses transmitted through the skin; the intensity of the stimulus is controlled directly by the patient in order to achieve better integration with the central nervous system. This invention effectively treats vascular disorders resulting from obstruction of the arteries of the legs, heart and brain because it induces vasodilatation and increases blood flow and the production of new blood vessels. The method also improves lesions of the spinal column, especially those affecting the back and neck, and other orthopaedic disorders.

This paper describes a system and method invention for blood vessels cleaning, such as a coronary artery, peripheral artery, or any other body vascular based on a mobile agent. The system consists of device which is electronically controlled, performing a procedure of vessel walls cleaning by removing the accumulated plaque or any other blockage material. This plaque or other blockage type may cause atherosclerosis and can eventually cause the artery to be blocked, causing heart disease, heart attack or stroke. Upon initial setup the system will be inserted into a human body and travel within its blood vessels. Based on sensors the system finds clogged areas and remove the blockage, without damaging the vessel's tissue using its cleaning system. The system independently and/or programmatically travels and searches for blockages within blood vessels using its own propulsion and navigation system. The system includes also a mechanism to remove and collect the removed plaque or any other blockage material. This system performs an efficient blood vessels cleaning and provides an innovative non surgical method for blood vessels blockage removal.

The invention relates to an auxiliary bandaging device for an elastic bandage, and belongs to the technical field of medical equipment. The auxiliary bandaging device is used for the postoperative hemostasis bandaging of the elastic bandage, and is characterized by comprising an upper fixing plate and a lower fixing plate, wherein the upper fixing plate is placed at a waist, the inner lateral surface of the upper fixing plate imitates the shape of the waist, and the outer lateral surface of the upper fixing plate is provided with salient points, grooves, fixing holes or sheaths; the lower fixing plate is placed outside thighs, the inner lateral surface of the lower fixing plate imitates the shapes of the thighs, and the outer lateral surface of the lower fixing plate is provided with salient points, grooves, fixing holes or sheaths; and the auxiliary bandaging device also comprises a front fixing plate an a rear fixing plate according to actual requirements. After patients do operation, the elastic bandage winds on the auxiliary bandaging device, so that the elastic bandage can be prevented from sliding and curling effectively; and compared with the conventional bandage hemostasis method, the auxiliary bandaging device has the advantage that after the auxiliary bandaging device is adopted, the bandage is not tied in flesh, so that the pain of the patients is relieved effectively. By using the auxiliary bandaging device for the elastic bandage, pressure can be reduced at any time according to actual requirements, so that the arterial occlusion of lower limbs and deep venous thrombosis of the patients are avoided.

A method for treating uterine leiomyomas, which includes vaginally accessing the cardinal ligament surrounding at least one uterine artery, and occluding the flow of blood through the least one uterine artery. The blood can be occluded by compression. The artery can be compressed by ligating the cardinal ligament. In addition, at least one uterosacral ligament can be ligated. In addition, the artery can be compressed by, clipping, stapling or clamping the cardinal ligament. The blood can also be occluded by coagulating the at least one artery. Coagulation can be done with a laser or a cauterizing device. A system for treating uterine leiomyomas, which includes vaginally accessing the cardinal ligament surrounding at least one uterine artery using a surgical suture passing device to extend a ligature around the ligament, and affixing a ligature around the cardinal ligament to occlude the flow of blood through at least one uterine artery. Also, a system for treating uterine leiomyomas, which includes vaginally accessing the cardinal ligament surrounding at least one uterine artery, providing an absorbable clip and/or staple, and affixing the clip and/or staple around the ligament to occlude the flow of blood through the at least one uterine artery.

Featured are methods for non-invasive assessment of vascular reactivity. The methods of the invention use phase contrast magnetic resonance imaging angiography and use the image data thereby acquired to measure shear rate, radius of the vasculature and flow through the vasculature. According to one aspect, such acquisition of image data occurs before and during, an arterial occlusion and according to another aspect such acquisition of image data occurs before during and after arterial occlusion. The disclosed methods of the invention allow for reproducible, non-invasive diagnosis of early stage indicators of atherosclerosis.

A method for digital thermal monitoring assessment of vascular function comprising a temporary arterial occlusion using a pneumatic cuff positioned on a subject's upper limb, monitoring skin temperature at the fingertip of the occluded limb for a period of time before, during, and after the occlusion, calculating a Zero Reactivity Curve based on variables including start temperature, room temperature, and the slope of temperature decline during the occlusion, and assessing vascular function based on comparing the Zero Reactivity Curve and the observed temperature rebound after the occlusion is removed. A vascular reactivity monitoring apparatus for measuring skin surface temperature comprising an inflatable cuff for placement around a subject's limb, a digital thermal measuring device and photoplethysmography measuring device for placement on a finger of the subject's limb wearing the cuff and a second digital monitoring device and photoplethysmography measuring device for placement on a finger of the subject's contralateral limb.

Devices, and methods for synchronizing cerebro-hemodynamic signals are disclosed. In one aspect, the devices and methods may include synchronizing first and second signals indicative of hemodynamic characteristics within a subject's brain. Differences may be determined between the synchronized signals and used to provide information for diagnosing changes in arterial occlusion. Differences between the synchronized signals may include differences, such as timing delays, between signature features of the synchronized signals. The first and second signals may be indicative of hemodynamic characteristics in first and second hemisphere's of a subject's brain. The first and second signals may be bioimpedance signals.

A thrombolysis catheter apparatus is disclosed comprising: (a) an elongated thrombolysis catheter portion comprising a plurality of independently controllable electroactive polymer actuators, which provide a curvature to the thrombolysis catheter based upon received control signals; (b) a control unit coupled to the plurality of actuators and sending the control signals to the plurality of actuators; and (c) an occlusion removal device. Also disclosed is a method of treating an arterial occlusion by advancing the thrombolysis catheter portion through the arterial vasculature of a patient to a position proximate the occlusion, while controlling the shape of the thrombolysis catheter portion using the control unit. The occlusion is then removed using the occlusion removal device.

A temporary aortic occlusion device is disclosed, having an expandable locator portion and an expandable occlusion portion. The expandable locator portion assists a user in determining whether the distal end of the device has been advanced within a patient's aorta, and the occlusion portion is expanded to occlude the patient's aorta, preferably below the renal arteries.

A method for the prevention or treatment of intraocular angiogenic diseases such as proliferative retinopathy, retinal vein occlusion, retinal artery occlusion or age-related macular degeneration, which comprises administering to a mammal (such as a human) in need thereof a pharmaceutically effective amount of an angiotensin II receptor antagonist such as 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazole-5-carboxylic acid.